Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: Are carbapenem alternatives achievable in daily practice?

International Journal of Infectious Diseases

Volumn 39, Issue , 2015, Pages 62-67

  Pilmis, B ^a,b   Delory, T ^c   Groh, M ^a   Weiss, E ^a   Emirian, A ^c   Lecuyer, H ^a   Lesprit, P ^c   Zahar, J R ^d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SAINT JOSEPH HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ D'ANGERS   (France)

Author keywords

Carbapenem; De escalation; Extended spectrum beta lactamase

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM DERIVATIVE; CEPHAMYCIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CATHETER; CATHETER INFECTION; CHILD; CLINICAL PRACTICE; COHORT ANALYSIS; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PROSPECTIVE STUDY; RELAPSE; URINARY TRACT INFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; ESCHERICHIA COLI INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84942532085     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.08.011     Document Type: Article

References (31)

1. Arpin C., Quentin C., Grobost F., Cambau E., Robert J., Dubois V., et al. Nationwide survey of extended-spectrum β-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother 2009, 63:1205-1214. 10.1093/jac/dkp108.
2. Meier S., Weber R., Zbinden R., Ruef C., Hasse B. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 2011, 39:333-340. 10.1007/s15010-011-0132-6.
3. Hoban D.J., Nicolle L.E., Hawser S., Bouchillon S., Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011, 70:507-511. 10.1016/j.diagmicrobio.2011.03.021.
4. Paterson D.L., Mulazimoglu L., Casellas J.M., Ko W.C., Goossens H., Von Gottberg A., et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000, 30:473-478. 10.1086/313719.
5. Pletz M.W., Rau M., Bulitta J., De Roux A., Burkhardt O., Kruse G., et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004, 48:3765-3772. 10.1128/AAC.48.10.3765-3772.2004.
6. Cantón R., Akóva M., Carmeli Y., Giske C.G., Glupczynski Y., Gniadkowski M., et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012, 18:413-431. 10.1111/j.1469-0691.2012.03821.x.
7. Rodríguez-Baño J., Alcalá J.C., Cisneros J.M., Grill F., Oliver A., Horcajada J.P., et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008, 168:1897-1902. 10.1001/archinte.168.17.1897.
8. Vardakas K.Z., Tansarli G.S., Rafailidis P.I., Falagas M.E. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012, 67:2793-2803. 10.1093/jac/dks301.
9. Retamar P., López-Cerero L., Muniain M.A., Pascual Á., Rodríguez-Baño J. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2013, 57(7):3402-3404. ESBL-REIPI/GEIH Group. 10.1128/AAC.00135-13.
10. Park S.H., Choi S.M., Chang Y.K., Lee D.G., Cho S.Y., Lee H.J., et al. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 2014, 69(10):2848-2856. 10.1093/jac/dku215.
11. Lee N.Y., Lee C.C., Huang W.H., Tsui K.C., Hsueh P.R., Ko W.C. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013, 56:488-495. 10.1093/cid/cis916.
12. Kim Y.K., Pai H., Lee H.J., Park S.E., Choi E.H., Kim J., et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002, 46:1481-1491.
13. Paterson D.L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000, 6:460-463.
14. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72. 10.1086/511159.
15. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J., Baron E.J., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect 2010, 11:79-109. 10.1089/sur.2009.9930.
16. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52:e103-e120. 10.1093/cid/ciq257.
17. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009; 136(5 Suppl) e28.
18. Revised surveillance case definition for HIV infection-United States, 2014. MMWR Recomm Rep 2014, 63(RR-03):1-10. Centers for Disease Control, Prevention (CDC).
19. Stevenson K.B., Khan Y., Dickman J., Gillenwater T., Kulich P., Myers C., et al. Administrative coding data, compared with CDC/NHSN criteria, are poor indicators of health care-associated infections. Am J Infect Control 2008, 36:155-164. 10.1016/j.ajic.2008.01.004.
20. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints, version 01/01/2014. Available at: (accessed March 31, 2014). http://www.eucast.org/.
21. Soussy C.J., Carret G., Cavallo J.D., Chardon H., Chidiac C., Choutet P., et al. [Antibiogram Committee of the French Microbiology Society. Report 2000-2001]. Pathol Biol (Paris) 2000, 48:832-871.
22. von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453-1457. 10.1016/S0140-6736(07)61602-X.
23. Delory T., De Pontfarcy A., Emirian A., About F., Berdougo B., Brun-Buisson C., et al. Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis. Eur J Clin Microbiol Infect Dis 2013, 32:1599-1604. 10.1007/s10096-013-1918-5.
24. Heenen S., Jacobs F., Vincent J.L. Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often?. Crit Care Med 2012, 40:1404-1409. 10.1097/CCM.0b013e3182416ecf.
25. Niederman M.S., Soulountsi V. De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia?. Clin Chest Med 2011, 32:517-534. 10.1016/j.ccm.2011.05.009.
26. Weiss E., Zahar J.R., Lesprit P., Ruppe E., Leone M., Chastre J., et al. Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams. Clin Microbiol Infect 2015, 21. 649.e1-649.e10. 10.1016/j.cmi.2015.03.013.
27. Giantsou E., Liratzopoulos N., Efraimidou E., Panopoulou M., Alepopoulou E., Kartali-Ktenidou S., et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007, 33:1533-1540. 10.1007/s00134-007-0619-x.
28. Leone M., Bourgoin A., Cambon S., Dubuc M., Albanèse J., Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003, 31:462-467. 10.1097/01.CCM.0000050298.59549.4A.
29. Tamma P.D., Han J.H., Rock C., Harris A.D., Lautenbach E., Hsu A.J., et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis 2015, 60(9):1319-1325. 10.1093/cid/civ003.
30. Bouza E., Torres M.V., Radice C., Cercenado E., de Diego R., Sánchez-Carrillo C., et al. Direct E-test (AB Biodisk) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia. Clin Infect Dis 2007, 44:382-387. 10.1086/510587.
31. Garnacho-Montero J., Gutiérrez-Pizarraya A., Escoresca-Ortega A., Corcia-Palomo Y., Fernández-Delgado E., Herrera-Melero I., et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014, 40:32-40. 10.1007/s00134-013-3077-7.